Cardiotoxicity of anticancer treatments: what the cardiologist needs to know (Q37788952)

23 August 2017

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know (English)

1 reference

23 August 2017

Michael S Ewer

1

1 reference

23 August 2017

Steven M Ewer

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Nature Reviews Cardiology

23 August 2017

1 reference

23 August 2017

7

1 reference

23 August 2017

10

1 reference

23 August 2017

564-575

1 reference

Neurotoxic and cardiotoxic effects of cocaine and ethanol

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Alcohol and cardiovascular diseases: a historical overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity profile of trastuzumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

A clinicopathologic analysis of adriamycin cardiotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Biophysical chemistry of the daunomycin-DNA interaction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Risk factors for doxorubicin-induced congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Assessment of anthracycline cardiomyopathy by endomyocardial biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiac safety of liposomal anthracyclines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomize

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Adriamycin cardiomyopathy--risk factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Elevated B-type natriuretic peptide levels after anthracycline administration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Mitoxantrone: an overview of safety and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Fulminant fatal cardiotoxicity following cyclophosphamide therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

ErbB2 is essential in the prevention of dilated cardiomyopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Mechanisms and models in heart failure: A combinatorial approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Deve

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Congestive heart failure is a rare event in patients receiving imatinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiac disturbances during the administration of taxol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Understanding and managing the possible adverse effects associated with bevacizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Mechanisms and models in heart failure: the biomechanical model and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Radiation-induced heart disease: review of experimental data on dose response and pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Myocardial infarction after irradiation in Hodgkin's disease: a review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Clinical and angiographic features of coronary artery disease after chest irradiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.121

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

31 March 2020

1 reference

12 December 2020

Effect of anthracycline antibiotics on oxygen radical formation in rat heart

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation

1 reference

12 December 2020

Anthracycline cardiomyopathy monitored by morphologic changes

1 reference

12 December 2020

Adult multicenter trials using dexrazoxane to protect against cardiac toxicity

1 reference

12 December 2020

Factors affecting late mortality from heart disease after treatment of Hodgkin's disease

1 reference

12 December 2020

[Myocardial ischaemia as a result of treatment with capecitabine]

1 reference

12 December 2020

Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies

1 reference

12 December 2020

Cyclophosphamide cardiac injury mimicking acute myocardial infarction

1 reference

12 December 2020

Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab.

1 reference

12 December 2020

10.1038/NRCARDIO.2010.121

Identifiers

DOI

1 reference

release_e2xzolowf5d73iqbrsc6hrc3sy

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e2xzolowf5d73iqbrsc6hrc3sy

24 November 2022

mapped directly with Wikidata item

1 reference